Top 50 Biotech Angel Investors in Europe (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
30 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Nadav Rosenberg
Angel
|
5 | United Kingdom, France, Israel | Seed, Pre-Seed, Series A | Biotechnology, Artificial Intelligence, Software | $850k–$19M |
|
Stefano Bernardi
Angel
|
5 | Italy, United Kingdom, France | Seed, Pre-Seed | Software, Biotechnology, Artificial Intelligence | $100k–$45M |
|
Bernard Majoie
Angel
|
4 | France, Belgium | Seed, Pre-Seed, Series A | Biotechnology, Medical, Health Care | $1.3M–$1.4M |
|
Charlie Songhurst
Angel
|
4 | United Kingdom, United States, Germany | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $510k–$8M |
|
Annie Vereecken
Angel
|
4 | Belgium | Seed, Series A | Medical, Biotechnology, Hospital | $2M–$27M |
|
Milad Alucozai
Angel
|
4 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $110k–$55M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
Sake Bosch
Angel
|
4 | The Netherlands, France, Israel | Seed, Series A, Series B | Software, E-Commerce, Biotechnology | $1.9M–$77M |
|
Bradley Horowitz
Angel
|
3 | United States, United Kingdom, Germany | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $150k–$120M |
|
DrPano Kroko Churchill
Angel
|
3 | United Kingdom | Angel, Series A | Health Care, Therapeutics, Biotechnology | $150k–$458k |
|
Peder Nielsen
Angel
|
3 | United Kingdom | Seed, Convertible Note | Biotechnology, Machine Learning | |
|
Jeff Dean
Angel
|
3 | United States, United Kingdom, Japan | Seed, Series A, Pre-Seed | Artificial Intelligence, Information Technology, Software | $450k–$53M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $854k–$7.1M |
|
Jude Gomila
Angel
|
3 | United States, United Kingdom, Canada | Seed, Pre-Seed, Angel | Software, Biotechnology, Information Technology | $190k–$4.7M |
|
Andrea Dusi
Angel
|
3 | Italy, United States, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Health Care, CleanTech | $150k–$15M |
|
Andrew Keys
Angel
|
3 | United States, India, Norway | Seed, Pre-Seed, Series A | Software, Finance, Blockchain | $1M–$34M |
|
Paul Wicks
Angel
|
3 | United Kingdom, United States, Japan | Seed, Pre-Seed, Series A | Software, Wellness, E-Commerce | $539k–$11M |
|
Ian Hogarth
Angel
|
3 | United Kingdom, United States, Germany | Seed, Series A, Pre-Seed | Software, E-Commerce, Artificial Intelligence | $668k–$28M |
|
Schnidar Harald
Angel
|
3 | Austria | Seed, Angel, Pre-Seed | mHealth, Software, Biopharma | |
|
David Helgason
Angel
|
3 | United States, Denmark, Finland | Seed, Series A | Software, Gaming, Information Technology | $1.1M–$30M |
|
Inaki Berenguer
Angel
|
3 | Spain, United States, United Kingdom | Seed, Angel, Pre-Seed | FinTech, E-Commerce, Financial Services | $233k–$8.5M |
|
Darrin Disley
Angel
|
3 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | $458k–$3.7M |
|
Taavet Hinrikus
Angel
|
3 | United Kingdom, United States, Estonia | Seed, Series A, Series B | FinTech, Software, Financial Services | $1M–$52M |
|
Romain Sautrau
Angel
|
3 | France, Denmark | Series A, Seed, Pre-Seed | Biotechnology, Agriculture, Video | $1.1M–$12M |
|
Pierre Drion
Angel
|
3 | Belgium | Series A, Series B | Biotechnology, Health Care, Life Science | $8.8M–$26M |
|
André-Jacques Auberton-Hervé
Angel
|
2 | France | Seed, Series A | Medical, Biotechnology | |
|
Carsten Maschmeyer
Angel
|
2 | Germany, Austria, Switzerland | Seed, Angel, Series A | Software, Information Technology, Apps | |
|
Bruce Linton
Angel
|
2 | Canada, United States, Denmark | Seed, Post-IPO Equity, Pre-Seed | Health Care, Cannabis, Biotechnology | |
|
Hugh Grant
Angel
|
2 | United Kingdom | Seed | Biotechnology, Machine Learning | |
|
Jon Oringer
Angel
|
2 | United States, United Kingdom, France | Seed, Pre-Seed | Software, Information Technology, E-Commerce | |
|
Leena Niemistö
Angel
|
2 | Finland, United States | Seed, Pre-Seed | Health Care, Software, E-Commerce | $480k–$3.2M |
|
Juan Knuth
Angel
|
2 | Spain | Seed, Series A | Health Care, Biotechnology, Digital Media | |
|
Tim Dempsey
Angel
|
2 | United Kingdom | Seed, Series A | Software, SaaS, Financial Services | $962k–$2.5M |
|
Nico Wittenborn
Angel
|
2 | United States, Germany, France | Seed, Series A, Series B | Software, Apps, Wellness | $1.6M–$88M |
|
Ariel Poler
Angel
|
2 | United States, Spain, Mexico | Seed, Series A, Angel | Software, Social Media, Internet | $455k–$7.9M |
|
Patrick Pichette
Angel
|
2 | United Kingdom, Germany, United States | Seed, Series A, Series B | Artificial Intelligence, Machine Learning, Software | $750k–$95M |
|
Sten Tamkivi
Angel
|
2 | Estonia, United States, United Kingdom | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Manufacturing | $120k–$35M |
|
Sophia Bendz
Angel
|
2 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed | Health Care, Software, Artificial Intelligence | $400k–$6.6M |
|
Serge Chiaramonte
Angel
|
2 | United Kingdom, United States, France | Seed, Pre-Seed | FinTech, Financial Services, Information Technology | $637k–$38M |
|
Nick Boyle
Angel
|
2 | United Kingdom | Seed | Biofuel, Agriculture, Artificial Intelligence | $3M–$3M |
|
Albert Wenger
Angel
|
2 | United States, Germany, Switzerland | Series A, Series B, Seed | Software, Manufacturing, Internet | $650k–$38M |
|
Vishal Gulati
Angel
|
2 | United Kingdom, Hungary | Seed, Series A, Series B | Biotechnology, Biopharma, Life Science | $2.1M–$30M |
|
Michael Novogratz
Angel
|
2 | United States, India, Germany | Seed, Series A | Blockchain, Cryptocurrency, FinTech | $953k–$38M |
|
Pratima Aiyagari
Angel
|
2 | United Kingdom, France, Croatia | Seed, Pre-Seed, Series A | Analytics, Cyber Security, SaaS | $982k–$12M |
|
Andrew Nutter
Angel
|
2 | France, United Kingdom, United States | Seed, Pre-Seed | Software, SaaS, FinTech | $550k–$4.9M |
|
Hampus Jakobsson
Angel
|
2 | Sweden, Denmark, United States | Seed, Angel, Series A | Health Care, Software, Artificial Intelligence | $96k–$33M |
|
Andreas Ehn
Angel
|
2 | Sweden, United States, Germany | Seed, Angel, Pre-Seed | Software, Internet, Financial Services | $740k–$7.7M |
|
Giampaolo Cagnin
Angel
|
2 | Italy, Denmark | Seed, Pre-Seed | Biotechnology, Food and Beverage, Plant-Based Foods | $4.2M–$7.8M |
|
Chris Mairs
Angel
|
2 | United Kingdom, United States | Seed, Pre-Seed, Angel | Software, FinTech, Financial Services | $334k–$3.9M |
| Access all 50 angel investors in Europe Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
- LIfT BioSciences — LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumors using its innate immunity platform. Its goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy.LIfT BioSciences was founded in 2016 andheadquartered in London, England.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Israel
Investor stats
- Total investments: 15
- Round size: Seed $850k–$3.1M; Pre-Seed $2M–$2M; Series A $18M–$19M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Italy, United Kingdom, France
Investor stats
- Total investments: 17
- Round size: Seed $100k–$45M; Pre-Seed $1.4M–$2.2M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- iubenda — Make your sites & apps legally compliant across multiple languages and legislations (including the GDPR) with our lawyer-crafted, self-updating solutions.
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- Golden — Golden is a developer of a self-constructing knowledge database used to accelerate discovery and education. The company uses and leverages human effort by using machine intelligence to make the process of gathering and communicating knowledge simpler.It combines a powerful search across several entities with fine-grain alerts to stay on top ofchanges, and semi-automatic research assistance for gaps in knowledge that enable people in organizations to stay current, understand and leverage the latest trends in their industry.
Bernard Majoie - President @ Fournier-Majoie
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: France, Belgium
Investor stats
- Total investments: 5
- Round size: Seed $1.3M–$1.4M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- reMYND — Driving the development of disease-modifying treatments
- AgenT — AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms.
- PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 180
- Round size: Seed $1.1M–$8M; Pre-Seed $510k–$5.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skrap — Skrap is an on-demand mobile marketplace for skip hire and other waste collection services.
- BirdyChat — BirdyChat is a Developer of a work chat application intended for work professionals.
- Hyphen SCS — Find and rent verified warehouses across 992+ cities in India. Compare 65,000+ listings on Hyphen SCS.
Annie Vereecken
Show more...Investment focus
- Industry: Medical, Biotechnology, Hospital
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 7
- Round size: Seed $2M–$6M; Series A $8.2M–$27M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 54
- Round size: Seed $150k–$6.7M; Pre-Seed $110k–$1.5M; Series A $13M–$55M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
Sake Bosch is a Founder and Managing Partner of Prime Ventures since 1999. Sake brings over 25 years of experience in marketing and sales and venture capital to Prime. Prior to founding Prime in 1999, Sake was a Senior Principal at Holland Venture and was responsible for managing investments in technology companies. Sake was involved in many ofthe Holland Venture technology investments including Applicare Medical Imaging (acquired by GE Medical Systems), BWise (acquired by Nasdaq), SQL Systems (acquired by Datastream) and Freecom (acquired by Mitsubishi Kagaku Media). Before joining Holland Venture in 1994, Sake worked as an Independent Corporate Finance Consultant focusing primarily on early stage companies. Prior to this position Sake was a Sales Executive at Securitas Group. Sake started his career in 1989 as a Strategic Market Analyst at VNU. Sake serves on the board of directors of Civolution, 4C, Dealerdirect, Digital Origin, Greetz, Forcare, SaaSPlaza, SlimPay and Takeaway.com. Previous investments include: 3mensio Medical Imaging (acquired by Esaoto), eBuddy (acquired by Booking.com), Global Collect (acquired by General Atlantic), MarketXS (acquired by Markit), Nedstat (acquired by comScore Inc.), Tridion (acquired by SDL) and Watermark (acquired by Qurius). Sake holds an M.Sc. degree in Business Administration as well as a B.A. degree in Management Science and Industrial Engineering.
Show more...Investment focus
- Industry: Software, E-Commerce, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: The Netherlands, France, Israel
Investor stats
- Total investments: 32
- Round size: Seed $1.9M–$9.5M; Series A $6.9M–$29M; Series B $7.1M–$77M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- LionVolt — LionVolt is a battery startup company that claims to develop the most efficient solid state lithium-ion battery.
- Fairbrics — Fairbrics is developing the first synthetic fiber with a net positive impact on climate change and capable of meeting the demand of the market.
- Multus — Key ingredients for the affordable scale-up of cellular agriculture
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 114
- Round size: Seed $150k–$18M; Series A $5.8M–$36M; Series B $19M–$120M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Key AI — Unlock new networking and career opportunities with Key, the leading AI-powered professional networking platform. Build and manage communities, host and join exclusive events, and create meaningful connections to supercharge your growth all in one place.
- OrgOrg — OrgOrg provides internal SaaS tools for organizational productivity suite for the companies
- Odyssey — Odyssey operates as an AI start-up, provides hollywood-grade visual AI.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Industry: Health Care, Therapeutics, Biotechnology
- Stage:Angel, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Round size: Angel $150k–$458k
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed, Convertible Note
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Japan
Investor stats
- Total investments: 93
- Round size: Seed $2.5M–$35M; Pre-Seed $450k–$3M; Series A $6.1M–$53M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Terraton — Terraton is a biochar platform that provides equipment, design, and financing to agribusiness operators.
- Moonlake AI — Vibe code games and worlds into existence.
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
Nicholas Francis is Co-founder at framebunker
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $854k–$7.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 55
- Round size: Seed $1.4M–$4.7M; Angel $190k–$1.3M; Pre-Seed $1M–$2.8M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
- Athens Research — Open-Source Roam Research. A private, extensible, and community-driven knowledge graph.
Entrepreneur and investor. After working in management consulting, in 2006 he created Wish Days, known above all for the Emozione3 gift boxes. In April 2016, he sold the company to the Smartbox group with a millionaire exit. In 2017, together with Cristina Pozzi, already a partner in Wish Days he founded Impactscool.He is advisor of dozens oftechnological initiatives and business angels in 150+ startups focusing on clean tech.He is the author of the book “Come far fallire una startup ed essere fellici” – How to make a startup fail and be happy, published by Bompiani, Bestseller in 2018.
Show more...Investment focus
- Industry: Biotechnology, Health Care, CleanTech
- Stage:Seed, Pre-Seed, Series A
- Geography: Italy, United States, United Kingdom
Investor stats
- Total investments: 15
- Round size: Seed $150k–$6M; Series A $3.8M–$15M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Talyn Air — Inspired by two-stage rockets, our innovative eVTOL uses two flight vehicles to transform flight. Fixed-wing performance with VTOL capabilities.
- BillionToOne — We are a team at the forefront of disease detection focused on moving Prenatal Screening and Liquid Biopsy forward.
- CaSRevolution — A novel disease-modifying approach against neurodegeneration
Andrew Keys is the Co-Founder and Managing Partner of Andrew Keys. He previously worked for ConsenSys as a Head of Global Business Development. Andrew Keys attended Loyola University Maryland.
Show more...Investment focus
- Industry: Software, Finance, Blockchain
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, India, Norway
Investor stats
- Total investments: 14
- Round size: Seed $1M–$34M; Pre-Seed $1.4M–$2.5M; Series A $14M–$15M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Stackr Labs — Micro-rollups to scale web3 applications
- Zivoe Finance — Join Zivoe in disrupting predatory high-interest lending.
- Ithaca Finance — Ithaca Finance a cross-chain derivatives trading and settlements protocol, is composed of an on-chain settlement layer with an innovative off-chain matching engine.
Paul Wicks, Ph.D., is a strategic advisor and independent consultant who helps digital health and life science companies turn data into evidence, evidence into influence, and influence into impact. He has supported over 40 organizations including AstraZeneca, Ada Health, Biogen, Click Therapeutics, and Woebot.Previously, Paul spent 13 years as VPof R&D at PatientsLikeMe, building one of the world’s largest patient communities and pioneering decentralized trials, digital biomarkers, and real-world evidence. He has authored over 200 peer-reviewed papers and served on editorial boards of journals including the BMJ, Digital Biomarkers, and BMC Medicine.A neuropsychologist by training, Paul completed his Ph.D. at King’s College London and a postdoc on the psychology of Parkinson’s disease. His work has been featured by BBC, CNN, and The New York Times. He was named MIT Technology Review’s “Humanitarian of the Year” in 2011 and is a TED Fellow and FLIER alumnus of the Academy of Medical Sciences. He is an honorary Professor at the University of Birmingham.
Show more...Investment focus
- Industry: Software, Wellness, E-Commerce
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, United States, Japan
Investor stats
- Total investments: 17
- Round size: Seed $3M–$6.6M; Pre-Seed $539k–$1M; Series A $6.9M–$11M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Epiminds — Epiminds develops multi-agent AI systems to run marketing end-to-end.
- Run Yourself — RunYourself is a prompt-driven, AI-assisted platform making it easy for managers to have effective coaching conversations. We blend expert coaching prompts on a spectrum of crucial topics with AI-powered support. This enables managers to have productive peer coaching conversations with other managers and more effective coaching, feedback, performance and career development conversations with their team members.
- MakeSense Technology — MakeSense is a team of tech experts, empowering people who are blind or have low vision.
Ian Hogarth is based out of London, England, and is the Chairman of Phasecraft. Ian previously worked at Songkick as a Chairman. Ian Hogarth attended the University of Cambridge.
Show more...Investment focus
- Industry: Software, E-Commerce, Artificial Intelligence
- Stage:Seed, Series A, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 55
- Round size: Seed $1.5M–$8.8M; Pre-Seed $668k–$7.7M; Series A $11M–$28M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Blloc — The ultimate smartphone experience. Boost your productivity. Focus on what matters.
- Cordless — Bridging the gap between voice and text
- Heygo — Explore places to visit within the UK and around the world on Rest Less. Get inspired and plan trips to holiday destinations with us.
Entrepreneur, Angel Investor, Scientist and Inventor
Show more...Investment focus
- Industry: mHealth, Software, Biopharma
- Stage:Seed, Angel, Pre-Seed
- Geography: Austria
Investor stats
- Total investments: 7
- Lead/follow: 86% lead, 14% follow
Portfolio highlights
- SCARLETRED — SCARLETRED is an international Digital Health Scaleup revolutionising the global skin care market by the AI powered SCARLETRED®VISION platform system. The problem we solved is subjective skin assessment and lacking standardization in Dermatology. Our medical device certified platform is fully mobile, runs via mobile App on smartphones and connectsto our web platform, which enables to generate smart imaging data and novel AI decision support applications in Dermatology and Telemedicine. The multi award winning technology is supplied international via SaaS to Biopharma and Cosmetics Industry, Hospitals and Medical Experts. Protected via worldwide patents it facilitates standardized skin documentation and remote tracking of skin changes and therapeutic effects via mobile App. Images can be uploaded in a cloud based platform and objectively analysed for visual skin changes over time, such as for allergic reactions, pigmentation changes, acne, psoriasis, disease or wound healing. SCARLETRED provides services on a broad range of dermatologic conditions ranging from B2B to B2B2C applications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!David is a technologist, the founder of Unity Technologies, non-exec director to others, and a restless entrepreneur with a passion for creating feedback loops between innovation and teams and products, applying new and old business models to changing industries, and pushing people to do the very best they can do.David's background is inprogramming, an assortment of university dabbling, creating companies, and helping entrepreneurs. He served as CEO of Unity Technologies since co-founding it in 2003 and until October 2014, with an unflinching vision to democratize game development, and to develop technology and business models for the next phase of the games industry. David Helgason attended the University of Copenhagen.
Show more...Investment focus
- Industry: Software, Gaming, Information Technology
- Stage:Seed, Series A
- Geography: United States, Denmark, Finland
Investor stats
- Total investments: 71
- Round size: Seed $1.1M–$8M; Series A $4.3M–$30M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Yousician — Yousician is a fun way to learn the guitar, piano, bass, ukulele or singing. Enjoy thousands of songs with Yousician as your personal music teacher!
- Absurd:Joy — absurd:joy is bringing joy to remote collaboration with Tangle
- Noice — Join the team build an awesome combo of social x playful x platform.
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- Industry: FinTech, E-Commerce, Financial Services
- Stage:Seed, Angel, Pre-Seed
- Geography: Spain, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Seed $500k–$8.5M; Angel $233k–$1M; Pre-Seed $1.2M–$2M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Ukio — Artfully designed fully furnished apartments available for extended stays
- Paack — Online sales growth and customer satisfaction are hampered by inadequate delivery experiences. Existing last mile delivery companies are incapable of providing a truly customer-centric approach. Our proprietary technology stack and operational excellence is built specifically to service time slot deliveries, controlled entirely by the endcustomer. This creates unprecedented results through basket conversion, loyalty, repeat purchase, acquisition, brand image and customer satisfaction, plus they can actually help the environment.Paack operates in Europe (UK, France, Spain and Portugal).
- Solid Financial Technologies, Inc — Instantly create bank accounts, send payments and issue cards, powered by the Solid Platform. Embedded Banking. Banking as a Service (BaaS) | Payments as a Service | Cards as a Service | Compliance as a Service
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Round size: Seed $458k–$3.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Taavet Hinrikus is based out of London, England and is the Partner of Plural Platform and Board Member of CoMind. Taavet previously worked at Wise as a Chairman and Co-founder. Taavet Hinrikus attended INSEAD.
Show more...Investment focus
- Industry: FinTech, Software, Financial Services
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Estonia
Investor stats
- Total investments: 125
- Round size: Seed $1M–$7.9M; Series A $7M–$47M; Series B $23M–$52M
- Lead/follow: 15% lead, 85% follow
Portfolio highlights
- Juro — Juro is an all-in-one contract automation platform that helps legal and business users to agree & manage contracts in one unified workspace.
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- Skeleton Technologies — Skeleton Technologies is the global leader in ultracapacitor & supercapacitor energy storage and helps companies in automotive, transportation, grid, and industry to save energy.
Romain Sautrau is a Investment Director at Supernova Invest. Romain attended INSEAD.
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Video
- Stage:Series A, Seed, Pre-Seed
- Geography: France, Denmark
Investor stats
- Total investments: 13
- Round size: Seed $1.4M–$7.8M; Series A $1.1M–$12M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Novolyze — Novolyze is a Food Safety company. They offer solutions to help the food industry manufacture safer food, while ensuring strong compliance with international Food Safety & Quality standards. Their research work mainly focuses on evaluating the inactivation of foodborne pathogens under different kinds of stress (heat, etc.). Based on thisexpertise, they have developed the first range of dried, ready-to-use surrogate bacteria, an innovation that allows the food industry to test the efficacy of microbial kill steps / intervention steps in real-life conditions. At Novolyze, they are at the forefront of Food Safety. Their cross-functional team of experts, mainly composed of food microbiologists and process engineers, is able to assist at multiple stages of a project. Novolyze relies on state-of-the-art infrastructures, installed in a pharmaceutical-grade environment at their R&D Center in Dijon, France.
- Antofenol — Antofénol is a post-harvest biocontrol company that directs and develops its work on the valorization of viticultural waste. Antofénol is an innovative biotechnology start-up providing ecological eco-extraction of plant matter.
- nextProtein — nextProtein is developing a large scale and sustainable insect based source of protein. The bioconversion of fly larvae fed with organic waste generates valuable feed components for fish, livestock and pets.
Pierre Drion - CEO @ Petercam
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B
- Geography: Belgium
Investor stats
- Total investments: 5
- Round size: Series A $8.8M–$14M; Series B $18M–$26M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- A-Mansia Biotech — A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering theintestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.
- Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
- Santero Therapeutics — This is the homepage of the website
Dr. André-Jacques Auberton-Hervé co-founded Soitec with Jean-Michel Lamure in 1992. As President, CEO and Chairman of the Board, Auberton-Hervé is responsible for overseeing the strategic, operational and financial activities of the company.Prior to founding Soitec, Auberton-Hervé managed several joint development programs between Leti andThomson-CSF, which focused on the technological transfer from R&D to production applications. These programs included the transfer of 1.2 µm and 0.8 µm SOI CMOS for space applications. He was also in charge of several projects, which applied SOI to 3D integration, VLSI and ULSI.In July of 2005, Auberton-Hervé was elected to serve as the European representative to SEMI’s International Board of Directors. His demonstrated vision, experience and leadership capabilities within the industry contributed to his appointment to the board. Auberton-Hervé is also the recipient of the 1999 European SEMI Award in recognition of his work on Smart Cut™ technology and his overall contributions to the semiconductor industry as a whole. Auberton-Hervé is a member of the Electrochemical Society and the IEEE.
Show more...Investment focus
- Industry: Medical, Biotechnology
- Stage:Seed, Series A
- Geography: France
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- LinKinVax — As part of our strategic evolution, EnnoDC has become the new trading name of LinKinVax. We're expanding our dendritic cell targeting technology and
Carsten Maschmeyer is a successful entrepreneur, consultant and financial investor. He was born on May 8, 1959 in Bremen and grew up in Hildesheim. After his graduation in 1978 Maschmeyer completed military service before he began to study medicine in Hannover. To finance his studies, he worked part-time in sales of investment advice to it in 1982completely dedicated financial advice. More about Carsten Masch Meyers consultant. In 1988 Carsten Maschmeyer to AWD financial group, which was successfully launched on the stock market in 2000 and rise to the MDAX and expanded in 11 countries. Was sold in 2007 Carsten Maschmeyer all his shares in the company at the insurance group Swiss Life, who renamed the AWD in AWD Holding. Maschmeyer has today different occupational focuses, inter alia, as entrepreneur, investor and consultant. His experience Carsten Maschmeyer a sought-after speaker on the subject of success. Motivated by the desire expressed by many listeners to learn more about his secret of success, Carsten Maschmeyer published in the spring of 2012 his book "Self Made - performance live richly". In it he describes the basis of his own exciting path and the celebrities strategies for professional, financial and personal success.
Show more...Investment focus
- Industry: Software, Information Technology, Apps
- Stage:Seed, Angel, Series A
- Geography: Germany, Austria, Switzerland
Investor stats
- Total investments: 78
- Lead/follow: no public data
Portfolio highlights
- Zeedz — Gaming for a green future. Zeedz is a monster collectible game that targets real-world climate change. Discover a world of plantified magic, made in Berlin.
- JobSwop.io — JobSwop.io is the employment software that allows you to find available positions but also filled ones for people looking to move jobs. The features of this app are Salary information, a Watch list, Area search, Integrated chat, Up to three Job profiles in one account, Document management.
- Bildungs urlauber — The goal of Bildungsurlauber.de is to make complicated topics simple. First and foremost, we assist you in locating the appropriate seminar for you by using simple filter options - regardless of whatever federal state you work in.
Mr. Linton is the founder of Canopy Growth Corporation (CGC) and co-founder of Tweed Marijuana Inc.Bruce’s primary focus has been to position cannabis brands in a competitive market and to raise the capital necessary to fund such operations. Bruce’s experience as a founder, CEO, and Board member across a wide variety of enterprises has influencedthe positive start of Canopy Growth, which to date has enjoyed market support for capital raises of over $150 million and the distinction of being the first company in the industry to be offered debt instruments by a federal lender. Bruce has led three M&A transactions valued over $500 million total since founding CGC. In addition to his leadership responsibility at Canopy Growth, Bruce is the CEO of communications company Martello Technologies. After beginning his career at Newbridge Networks Corporation, he has since held positions that include General Manager and Re-Founder of Computerland.ca, President and Co-Founder of webHancer Corp, and part of the establishing team at CrossKeys Systems Corporation. He was also part of the leadership team for the NASDAQ/TSX initial public offering at CrossKeys. Bruce has been responsible for the acquisition and/or disposition of over $600 million in business assets, and has established regular engagement with the World Bank and Asia Development Bank while focused on markets in India, Philippines, China, Peru, Colombia, Ecuador, Azerbaijan and Uzbekistan. He is the past Chairman of the Ottawa Community Loan Foundation, past Board Member and Treasurer of Canada World Youth past Board of Governor for Carleton University, past President of the Nepean Skating Club and past President of the Carleton University Students Association.
Show more...Investment focus
- Industry: Health Care, Cannabis, Biotechnology
- Stage:Seed, Post-IPO Equity, Pre-Seed
- Geography: Canada, United States, Denmark
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Omura — Discover heat-not-burn technology with Omura's dry herb vaporizer devices. Explore sustainable vaping options for hemp & whole flower CBD.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Martello Technologies — Prioritize and resolve performance problems and optimize the Microsoft 365 and Teams user experience with Martello Vantage DX.
Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more...Investment focus
- Industry: Biotechnology, Machine Learning
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Seed, Pre-Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 108
- Lead/follow: no public data
Portfolio highlights
- Jome — On our platform, you can search for and tour thousands of new construction homes and communities near you. Our new home experts are ready to guide you through the entire home-buying process and will help you turn your dream home into a reality
- Unsloth AI — Open source fine-tuning & reinforcment learning (RL) for gpt-oss, Llama 4, DeepSeek-R1, Gemma, and Qwen3 LLMs! Beginner friendly.
- OneImaging — OneImaging makes life-saving diagnostics affordable, accessible, and personal. We connect employers, health plans, and members to a trusted national network of imaging centers, delivering faster answers with transparent pricing and premium care across MRIs, CT scans, ultrasounds, mammograms, X-rays and more. We serve organizations looking to control medical spend and individuals who need reliable results without delays. Every scan booked through OneImaging is proof that healthcare can be simpler, cheaper, and kinder.
Leena Niemistö
Show more...Investment focus
- Industry: Health Care, Software, E-Commerce
- Stage:Seed, Pre-Seed
- Geography: Finland, United States
Investor stats
- Total investments: 18
- Round size: Seed $480k–$3.2M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- ADESANTE — SurgeryVision is a Virtual Reality solution for Surgeons. Product is intended to be used for planning surgical procedures.
- Maire — Maire - AI co-pilot for industry leading B2C E-commerce brands. From Industry Trends to Market Research and Search Intent Analysis
- Finnadvance — Finnadvance is an Organ-On-Chip company developing high throughput biological barriers on chips to mimic human biology such as vascular, lung and the Blood-Brain-Barriers for small molecule, micro-nano-formulation permeability and toxicity testing with in-vivo like dynamic cell cultures.
Juan Knuth
Show more...Investment focus
- Industry: Health Care, Biotechnology, Digital Media
- Stage:Seed, Series A
- Geography: Spain
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Devicare — Devicare designs point-of-care medical devices that monitor, diagnose and treat chronic diseases. The company's medical devices are useful in measuring the level of biomarkers in body fluids such as saliva, tears, sweat, sputum, feces, urine or blood, enabling medical professionals to detect and treat various infectious diseases.
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more...Investment focus
- Industry: Software, SaaS, Financial Services
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 16
- Round size: Seed $962k–$2.5M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Nico Wittenborn is an Investor at Adjacent.
Show more...Investment focus
- Industry: Software, Apps, Wellness
- Stage:Seed, Series A, Series B
- Geography: United States, Germany, France
Investor stats
- Total investments: 42
- Round size: Seed $1.6M–$8.5M; Series A $7.1M–$30M; Series B $7.5M–$88M
- Lead/follow: 52% lead, 48% follow
Portfolio highlights
- Niantic — Niantic’s mission is to use emerging technology to enrich our experiences as human beings in the physical world. We seek to build products that inspire movement, exploration, and face-to-face social interaction. Originally formed at Google in 2010, we are now an independent company with a strong group of investors including Nintendo, The PokémonCompany, and Alsop Louie Partners. We’re focused on building games that get people outside and exploring by enabling our players to have fun while visiting new places, learning about the world around them, and meeting new friends. We’ve launched Ingress, an immersive real-world mobile game played by millions of people; it's been downloaded more than 20 million times and is played in over 200 countries and territories worldwide. We've also developed Pokémon GO, which has broken records around the world and has been downloaded more than 750 million times in its first year.
- Backbone — Backbone is a mobile gaming controller with intuitive controls, clickable thumbsticks & zero latency that works with cloud and remote gaming.
- Sunnyside — Sunnyside is the #1 alcohol moderation app helping 600,000+ people drink less through tracking, coaching, and optional naltrexone via telehealth. Start your free 15-day trial.
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more...Investment focus
- Industry: Software, Social Media, Internet
- Stage:Seed, Series A, Angel
- Geography: United States, Spain, Mexico
Investor stats
- Total investments: 45
- Round size: Seed $455k–$7M; Angel $1M–$1.7M; Series A $3M–$7.9M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Goin — Goin is a mobile application to save money easily and take advantage of it without knowing how to invest, through Machine Learning algorithms that allow you to accumulate the user's money through small daily gestures. he three Spanish founders, David, Carlos and Gabriel, were looking for a way to optimize their own money, and decided toconduct an experiment by exchanging their debit cards and thus saving 62% during those two months of rehearsal. This is how Goin emerged, which aims to meet the needs of 100% of Millennials, of which 83% confess that they do not know how to save, making available an easy-to-use tool that enhances their finances and lifestyle. On the one hand, the Barcelona startup allows the user to add money automatically and multiply it without having previous knowledge of investment. Goin uses a simple system that first asks to know the user through questions about their habits and, in this way, they are offered automatic systems and methods of saving. Once the user adds money to the app, they can transfer part or all of it to investment, or to their bank account. Its Smart Saving technology manages to accumulate money with small, everyday gestures, such as rounding a payment.
- Kiwibot — Delivery robots to optimize your business and deliver safely and timely to your customers.
- Grin Scooters — Grin Scooters is a software company that operates network of operational shared electric scooters. Currently, Grin only operates in Mexico City, Guadalajara, Monterrey, Sao Paulo and Bogota but it has plans to expand to other cities throughout Latin America.
Patrick Pichette is based out of London, England, and is the Partner of Inovia Capital and also Board Member of Cohere. Patrick Pichette previously worked at Twitter as a Board of Directors. Patrick Pichette attended the University of Oxford.
Show more...Investment focus
- Industry: Artificial Intelligence, Machine Learning, Software
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Germany, United States
Investor stats
- Total investments: 23
- Round size: Seed $750k–$10M; Series A $10M–$95M; Series B $15M–$95M
- Lead/follow: 13% lead, 87% follow
Portfolio highlights
- Apheris — Superior drug discovery models through federated data networks
- Boost Technology — Enabling informal small businesses to thrive in Africa's emerging digital economy
- made of air — Made of Air is a carbon-negative materials company. They take low-value wood waste and transform it into high-value, carbon-negative thermoplastics. These thermoplastics can be formed with all traditional heat-forming methods and used for a wide variety of applications, turning manufactured goods into engineered carbon sinks.
Sten Tamkivi is the Chief Product Officer at Topia (formerly MOVE Guides). He was previously co-founder and CEO of Teleport (acquired by Topia), the place to scout for startup people. He co-founded the company as an EIR at Andreessen Horowitz.Sten has been a tech entrepreneur since 1996. After founding a few companies in Estonia, he joined Skypeas an early executive, ran the original R&D office, and held several global product leadership roles for 8+ years.He has an MS in Management from Stanford GSB.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Pre-Seed
- Geography: Estonia, United States, United Kingdom
Investor stats
- Total investments: 45
- Round size: Seed $540k–$20M; Pre-Seed $120k–$2.2M; Series A $7.1M–$35M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Katana — Katana gives thousands of manufacturers a live look at their business with visual, intuitive, and easy-to-use ERP software.
- Insempra — Origin.Bio creates synthetic microorganisms that can make many of the same ingredients as traditional chemical industrialization processes today, but with significantly fewer energy requirements and waste produced while eradicating the need for petrochemicals.The company drives the convergence of engineering with biology, using DNA as theprogramming language. Rather than editing genetic material only in or out of DNA, engineers can hack entirely new organisms that have never existed — all powered by computing, automation, and artificial intelligence (AI)/machine-learning while leveraging millions of years of evolution. Operating at an atomic level, the company farms organisms with microscopic precision and integrates them into existing original equipment manufacturer (OEM) manufacturing processes. This asset-light approach enables Origin.Bio to generate sustainable materials at speed in a cost-effective way, without compromising on performance.
- Entrepreneurs First — We turn exceptional individuals into funded founders. We back you first, then give you a bridge to Silicon Valley.
Sophia Bendz - Partner @ Cherry Ventures
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 46
- Round size: Seed $400k–$6.6M; Pre-Seed $800k–$2M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- mayk — Mayk sounds. Mayk music. Mayk noise. Mayk it... In an app.
- Mantle — Welcome to MANTLE - Scandinavian professional skincare elevated by cannabis.
- Vira Health — Clinically-backed support for your global workforce, from family building through midlife and beyond.
Serge Chiaramonte
Show more...Investment focus
- Industry: FinTech, Financial Services, Information Technology
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, France
Investor stats
- Total investments: 57
- Round size: Seed $1.2M–$5.3M; Pre-Seed $637k–$38M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
- qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
- Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.
Show more...Investment focus
- Industry: Biofuel, Agriculture, Artificial Intelligence
- Stage:Seed
- Geography: United Kingdom
Investor stats
- Total investments: 2
- Round size: Seed $3M–$3M
- Lead/follow: 100% lead, 0% follow
Portfolio highlights
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Albert Wenger is a managing partner at Union Square Ventures. Before joining USV, Albert was the president of del.icio.us through the company’s sale to Yahoo and an angel investor (Etsy, Tumblr). He previously founded or co-founded several companies, including a management consulting firm and an early hosted data analytics company. Albert graduatedfrom Harvard College in economics and computer science and holds a Ph.D. in Information Technology from MIT.
Show more...Investment focus
- Industry: Software, Manufacturing, Internet
- Stage:Series A, Series B, Seed
- Geography: United States, Germany, Switzerland
Investor stats
- Total investments: 104
- Round size: Seed $650k–$13M; Series A $1M–$38M; Series B $4.3M–$30M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- DiviGas — DiviGas is an oil and gas company that developed a new process for manufacturing membranes which has yielded vastly superior results to what a membrane can do. The company was founded in 2019 and headquartered in Central Region, Singapore.
- Carbo Culture — We are a project developer with proprietary climate technology. We are building a rapidly scalable biochar carbon removal solution.
- Marvel Fusion — Marvel Fusion is a developer of fusion energy technology used to offer environment-friendly and safe energy. Its reactor is based on the short pulse, high energy, and electrically efficient laser that is suited for commercializing baseload fusion electrical power helping consumers to access clean, safe, and reliable energy sources.The company wasfounded in 2019 and is headquartered in Munich, Bayern.
Vishal Gulati: Vishal serves as a venture partner specialising in digital health at DFJ Esprit, Europe's leading Silicon Valley style venture capital firm with over $1b under management. Since 2012, Vishal has been Europe’s leading promoter of investment into the emerging digital health sector and chairman of Digital Health Forum, whichsupports the best in class digital health companies to grow into global enterprises. Vishal serves on several boards including Horizon Discovery Group PLC (Cambridge, UK), a gene editing company; Fluidics Analytics (Cambridge, UK), a next gen protein discovery engine, Frameshift a healthcare information flow platform (London, UK) and EcoEos (San Francisco, USA), a consumer genomics business. His previous investments include Napo Pharmaceuticals, Glenmark, Renovo and Phagenesis.
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Life Science
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, Hungary
Investor stats
- Total investments: 8
- Round size: Seed $3.2M–$8M; Series A $2.1M–$12M; Series B $6.8M–$30M
- Lead/follow: 25% lead, 75% follow
Portfolio highlights
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
- Verisian — Verisian accelerates drug time to market with the industry's first platform offering real study traceability (CDISC, SDTM, ADaM, TFLs)
- Turbine — Turbine is virtualizing biological experiments with AI to accelerate drug discovery and enhance clinical translatability.
Michael E. Novogratz is based out of New York, New York, and is the Founder and CEO of Galaxy Digital. Michael previously served at Partner and President of Fortress Investment Group. Michael E. Novogratz attended Princeton University.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, FinTech
- Stage:Seed, Series A
- Geography: United States, India, Germany
Investor stats
- Total investments: 33
- Round size: Seed $953k–$8M; Series A $11M–$38M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Verandah — Verandah is story based conscious luxury resort brand retailing amongst the top 100 in the global luxury resort wear space with design roots strongly based in India. Verandah also has a line of 100% Italian made sustainable swimwear to compliment the season-less ready to wear line.
- CryptoQuant — CryptoQuant is a community-driven analytics platform to lower hurdles of data-based decisions. Crypto investors often fail to make data-based decisions due to a lack of time and knowledge. We lower the hurdles of data-based decisions by saving research time and decreasing the knowledge gap.
- Cambrian Biopharma — Cambrian is developing a raft of new companies and therapies to extend healthy lifespan, bringing proven scientific and organizational expertise to exceptional research teams worldwide.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Industry: Analytics, Cyber Security, SaaS
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Croatia
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$5.5M; Pre-Seed $982k–$1.2M; Series A $12M–$12M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Mindflow — Mindflow is a No-Code & Agentic Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks and to deploy AI Agents at scale.
- ESPROFILER — ESPROFILER uniquely combines security spend, commercials, and capabilities with threats helping security leaders maximise their investments.
Andrew Nutter is a Co-Founder at Gama. He attended Stanford University.
Show more...Investment focus
- Industry: Software, SaaS, FinTech
- Stage:Seed, Pre-Seed
- Geography: France, United Kingdom, United States
Investor stats
- Total investments: 25
- Round size: Seed $550k–$4.9M; Pre-Seed $809k–$3.3M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Yavin — Yavin provides modern point-of-sale solutions for European merchants
- Jump — Jump takes the hassle out of being a freelancer. We accompany hundreds of freelancers in their daily lives by securing their adventure. Relax, we take care of everything.
- Core Biogenesis — Biodesigning the Future of Regenerative Medicine & Skincare
Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.
Show more...Investment focus
- Industry: Health Care, Software, Artificial Intelligence
- Stage:Seed, Angel, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 43
- Round size: Seed $310k–$5.3M; Angel $96k–$1.2M; Series A $2.3M–$33M
- Lead/follow: 12% lead, 88% follow
Portfolio highlights
- LifeX — LifeX offers furnished and serviced private rooms in coliving apartments or private apartments in central locations in Copenhagen, London, Paris, Berlin, Munich, Halle and Aarhus. Enjoy all-inclusive prices, flexible rental terms and a built-in community of young professionals.
- Neurolabs — Neurolabs helps puts an end to out-of-stocks using a powerful combination of computer vision and synthetic data, improving customer experience and increasing revenue.
- ClimateView — ClimateView is a Swedish climate action technology company that helps cities transform climate planning into progress. We combine data, agent-based modelling and interface design to help cities successfully manage the transition to zero carbon economies.
Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.
Show more...Investment focus
- Industry: Software, Internet, Financial Services
- Stage:Seed, Angel, Pre-Seed
- Geography: Sweden, United States, Germany
Investor stats
- Total investments: 18
- Round size: Seed $740k–$7.7M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Leetify — We help gamers identify their weaknesses, work on those weaknesses and track their progression.
- Mavenoid — Mavenoid is the only product support automation platform built for complex products and devices. Using our unique AI, we solve problems too complex for chatbots
- Antler — Build your next company with Antler, a global day zero investor enabling exceptional founders to start great companies, from the very beginning. Apply now!
Giampaolo’s aim has always been to apply a disruptive approach to functional food ingredients and that’s how he founded Italiana Ingredienti in ’89 and Campus in ’05. Both companies have been acquired, Italiana Ingredienti by Chr. Hansen in ‘99 and Campus by Firmenich in ’18. Today he serves as Founder and Chairman at Hi-Food, an Italian companyproviding key functional ingredients to food companies, and as a business Angel Investor in several startups.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Plant-Based Foods
- Stage:Seed, Pre-Seed
- Geography: Italy, Denmark
Investor stats
- Total investments: 3
- Round size: Seed $4.2M–$7.8M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Chromologics — Chromologics produce natural sustainable colors. Our flagship product is ChromoRed which performs better than existing natural, red colorants. ChromoRed is also applicable with vegan, kosher and halal diets.
- Dreamfarm — We are a team of food-lovers 100% made in Italy! We dreamt of a better, tastier, more sustainable future and decided to join forces to create something special.
Chris Mairs - Venture Partner @ Entrepreneurs First
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Pre-Seed, Angel
- Geography: United Kingdom, United States
Investor stats
- Total investments: 25
- Round size: Seed $655k–$3.9M; Angel $334k–$707k; Pre-Seed $917k–$2M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- nMachine — A Low-Code solution for creating extraordinary Day 2 Operations platforms - called nMachines - for your existing Kubernetes-based applications, that can be shared inside and outside your organization.
- Incard — Welcome to the world's first payment solution designed exclusively for e-commerce, entrepreneurs, dropshippers and influencers. Join our waitlist now.
- Tuza — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Angel Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 angel investors investing in Europe Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!